Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 8933 results

  1. Pernicious anaemia

    Awaiting development Reference number: GID-QS10130 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Advocacy services for adults with health and social care needs

    Awaiting development Reference number: GID-QS10145 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [TSID12305]

    Awaiting development Reference number: GID-TA11933 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

    Health technology evaluations
    In development

  8. ID6611 Obesity, overweight - semaglutide (including review of TA875)

    Awaiting development Reference number: GID-TA11851 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  10. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Deucravacitinib for treating active psoriatic arthritis [TSID11981]

    Awaiting development Reference number: GID-TA11510 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]

    Awaiting development Reference number: GID-TA11198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development